What is the recommended evaluation and management for leukocytoclastic vasculitis?

Management of Leukocytoclastic Vasculitis

Immediately discontinue any suspected culprit medication—this single intervention alone often resolves drug-induced leukocytoclastic vasculitis without requiring immunosuppression. 1, 2

Initial Evaluation: Distinguish Isolated Cutaneous from Systemic Disease

Your primary diagnostic goal is to determine whether this is benign drug-induced/isolated cutaneous disease versus life-threatening systemic vasculitis requiring aggressive immunosuppression. 1, 3

Essential Workup

• Complete blood count (check for neutropenia in levamisole cases) 1
• Urinalysis and renal function (glomerulonephritis indicates systemic disease) 1, 3
• ANCA testing (both immunofluorescence and ELISA) 1, 3
• Hepatitis B and C serology 3
• ANA and antihistone antibodies 1
• Complement levels (C3, C4) 3
• Skin biopsy with direct immunofluorescence (check for IgA deposition) 3, 4

Red Flags for Systemic ANCA-Associated Vasculitis

• Mononeuritis multiplex (this mandates aggressive therapy) 1
• Glomerulonephritis or pulmonary hemorrhage 1
• Low-titer MPO-ANCA with single antigen specificity (not dual MPO/PR3) 1
• Concordant ANCA immunofluorescence and ELISA results 1

Clues Suggesting Benign Drug-Induced Disease

• High-titer MPO-ANCA or dual MPO/PR3 positivity 1, 2
• Discordance between ANCA immunofluorescence and ELISA 1, 2
• Positive ANA and antihistone antibodies 1, 2
• Isolated cutaneous involvement without renal or pulmonary disease 1, 2
• Neutropenia with retiform purpuric rash (levamisole-induced) 1

Treatment Algorithm

For Isolated Cutaneous or Drug-Induced Disease

Step 1: Drug Discontinuation

• Stop hydralazine, propylthiouracil, levamisole-adulterated cocaine, minocycline, levetiracetam, or warfarin 1, 2
• This alone typically induces resolution 2, 3

Step 2: Supportive Care

• Compression stockings and leg elevation 4
• Avoid prolonged standing or walking 3

Step 3: Add Corticosteroids ONLY for Severe Cutaneous Features

• Prednisolone 1 mg/kg/day (maximum 60 mg/day) only when hemorrhagic blisters or incipient skin necrosis appear 1, 2
• Do NOT routinely use corticosteroids for simple palpable purpura 1

Step 4: Chronic or Relapsing Disease

• Colchicine 0.6 mg twice daily as first-line therapy (superior safety profile to long-term corticosteroids) 1, 2, 4
• Dapsone as second-line option 4

For Confirmed Systemic ANCA-Associated Vasculitis

Critical Pitfall: Never use cyclophosphamide or rituximab for isolated cutaneous or drug-induced disease—these carry significant toxicity and are reserved exclusively for organ-threatening systemic vasculitis. 1, 2

Induction Therapy for Organ-Threatening Disease:

• Cyclophosphamide (oral 2 mg/kg/day, max 200 mg/day, or IV pulses) PLUS prednisolone 1 mg/kg/day (max 60 mg/day) 1
• Rituximab is an evidence-based alternative to cyclophosphamide 1

Maintenance Therapy After Remission:

• Azathioprine, methotrexate, or rituximab to sustain disease control 1

Long-Term Monitoring:

• Surveillance for cardiovascular risk factors 1
• Monitor for osteoporosis, infections, and hypogammaglobulinemia (especially with rituximab) 1
• Coordinate care with specialized vasculitis centers 1

Prognosis

Drug-induced leukocytoclastic vasculitis has favorable prognosis with drug discontinuation alone. 1 Conversely, when systemic ANCA-associated vasculitis is the underlying cause, long-term specialist follow-up is mandatory. 1, 3